Keywords: Novo Nordisk, Victoza, Lilly, Amylin, Alkermes, Bydureon, EADS, Type 2 diabetes

Strong new data on Novo Nordisk’s Victoza and Lilly/Amylin’s Bydureon presented at EADS

Article | 13 September 2011

Print This

A significantly higher proportion of patients reached the target for blood sugar control (HbA1c target <7%) when Danish insulin ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in